Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Contegra

This article was originally published in The Gray Sheet

Executive Summary

Pulmonary valved conduit receives FDA Humanitarian Device Exemption approval, firm announces Nov. 24. The bioprosthetic, composed of a bovine jugular vein containing an integral valve that can be used to reconstruct a blood pathway from the right ventricle to the lungs, corrects congenital defects of the right side of the heart in patients under 18. Contegra can be used instead of a human valve, supplies of which are limited, Medtronic notes. The company has been distributing the device outside the U.S. since 1998 and acquired the product from VenPro in 2001...

You may also be interested in...



FDA Assembling Advisors To Discuss Pediatric HDE Products

As part of a periodic review, FDA is bringing together experts to review several products that are conditionally available for pediatric use under the agency's Humanitarian Device Exemption program.

Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.

CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus

Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel